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Rescue Angioplasty Superior to Repeat Fibrinolysis
The majority of patients with ST-segment elevation myocardial infarctionsare treated with fibrinolytics, but nearly one-half do not successfully reper-
fuse. The optimal therapy for failed fibrinolysis is controversial. Wijeysundera and
colleagues performed a meta-analysis of 8 trials to determine if either rescue
percutaneous coronary intervention (PCI) or repeat fibrinolysis was superior to no
further intervention. Rescue PCI resulted in a substantial reduction in a composite
end point of all-cause mortality, reinfarction, and heart failure, with a relative risk
reduction of 28%. Repeat fibrinolysis was not superior to conservative therapy.
From this data, rescue PCI appears superior to repeat fibrinolytic therapy for failed
fibrinolysis. See page 422.
Coronary Artery Disease
CXCL16 is a Marker of Inflammation and Atherosclerosis
CXCL16 is a protein expressed predominantly on macrophages which recognizes
oxidized low-density lipoprotein, among other stimuli, and stimulates other inflam-
matory pathways. Lehrke and colleagues performed a series of studies to address its role
in the initiation and progression of atherosclerosis. Highlights from their findings
include the result that soluble levels of CXCL16 are higher in patients with acute
coronary syndromes and that expression of CXCL16 can be reduced by aspirin and
peroxisome proliferator-activated receptor-gamma agonists, such as pioglitazone.
Overall, these findings suggest that CXCL16 may play a pro-inflammatory role in
atherosclerosis, particularly during acute coronary syndromes. See page 442.
Page 454
Heart Failure
Beneficial Effects of CPAP for Patients With OSA and CHF
The repeated apnea-arousal cycles that characterize obstructive sleep apnea (OSA)lead to altered cardiac loading conditions, hypoxia, and sympathetic nervous
system activation, conditions that are probably detrimental in patients with congestive
heart failure (CHF). Yoshinaga and colleagues studied the effects of both short and
long-termcontinuous positive airway pressure (CPAP) therapy in 7patientswithCHF
and OSA. Initially, CPAP reduced stroke volume and cardiac oxidative metabolism;
longer-term CPAP improved left ventricular ejection fraction and reduced oxidative
metabolism. These effects are similar to the effects seen with beta-blocker therapy for
CHF, suggesting a potential role for CPAP in patients with CHF and OSA. See
pages 450 and 459. See figure.
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Cardiovascular Pharmacology
Urocortin 2 Infusion Increases Cardiac
Output, Decreases Systemic Vascular Resistance
Urocortin 2 is one of the corticotrophin-releasing-factor peptides; recent researchsuggests that it may have beneficial effects for treating heart failure. Davis and
colleagues describe the first experience of infusing this peptide into healthy volunteers
in a dose titration study. The higher dose was found to nearly double cardiac output
with a fall in systemic vascular resistance of almost 50%; the side-effects were minor.
Urocortin 2 appears to merit further study as a potential way to temporarily increase
cardiac output. See page 461. See figure.
Page 477
Diastolic Dysfunction
Diastolic Dysfunction Predicts Poor Outcomes in Sickle Cell Disease
Pulmonary hypertension is a known risk factor for death in patients with sickle celldisease (SCD), but whether this reflects increased resistance in the lung paren-
chyma or is related to left ventricular failure is unknown. Sachdev and colleagues
performed echocardiograms on over 200 patients with SCD. Evidence of diastolic
dysfunction was present in 18% of patients. Diastolic dysfunction was associated with
a relative risk of death of 3.5; the presence of both diastolic dysfunction and pulmonary
hypertension conferred a risk ratio of 12.0. In this study, diastolic dysfunction and
pulmonary hypertension independently and synergistically predicted increased mor-
tality in patients with SCD. See page 472. See figure.
